Spanish Registry of Esophagogastric Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Surgery, Chemotherapy, anti-targeted agents and immunotherapy, Radiotherapy.
- Who it may be relevant to
- Registry conditions: Esophageal Cancer, Gastric Cancer. Basic parameters: 18 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer
Overview
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
Detailed description
Patient data will be collected from medical records retrospectively.
Interventions
- Procedure Surgery
Surgery - Drug Chemotherapy, anti-targeted agents and immunotherapy
Chemotherapy, anti-targeted agents and immunotherapy - Radiation Radiotherapy
Radiotherapy
Primary outcome measures
- Diagnostic and therapeutic approach [Time frame: Up to 12 months]
Secondary outcome measures (8)
- Epidemiological profiles [Time frame: Up to 12 months]
- Risk factors [Time frame: Up to 12 months]
- Pathological features [Time frame: Up to 12 months]
- Clinical and diagnostic approach [Time frame: Up to 12 months]
- Treatments adjusted to prognostic variables [Time frame: Up to 12 months]
- Validate and compare prognostic models [Time frame: Up to 12 months]
- Prognostic factors [Time frame: Up to 12 months]
- Create and validate a predictive model [Time frame: Up to 12 months]
Eligibility criteria
Inclusion criteria
- Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
- Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.
Exclusion criteria
- A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Spain · 38 centers
- Hospital General Universitario de Alicante — Alicante
- Hospital General Universitario de Elche — Elche
- Hospital General Universitario de Elda — Elda
- Hospital Universitario Reina Sofia — Córdoba
- Hospital Regional Universitario de Málaga — Málaga
- Hospital Universitario Virgen Macarena — Seville
- Hospital Universitario Virgen del Rocio — Seville
- Hospital Universitario Son Espases — Palma de Mallorca
- … and 30 more centers
Identifiers
NCT: NCT04958720 · 2020-01 · RXSCXJ3E6E